Pharmacological heterogeneity limits antidepressant study

A third study used lofepramine as a comparitor, a more modern tricyclic with a much more benign anticholinergic side effect profile than its older cousins, which have an adverse event rate similar to the selective serotonin reuptake inhibitors. 2 Two of the three studies providing unambiguous data f...

Full description

Saved in:
Bibliographic Details
Published inBMJ Vol. 327; no. 7409; p. 289
Main Author Hale, Anthony S
Format Journal Article
LanguageEnglish
Published England British Medical Association 02.08.2003
BMJ Publishing Group LTD
BMJ Publishing Group
BMJ Publishing Group Ltd
EditionInternational edition
Subjects
Amitriptyline - therapeutic use
Antidepressants
Antidepressive Agents - therapeutic use
Depressive Disorder - drug therapy
Depressive disorders
Humans
Letters
Mianserin - therapeutic use
Paroxetine - therapeutic use
Pharmacology
Reuptake
Serotonin
Serotonin agents
Serotonin Uptake Inhibitors - therapeutic use
Studies
Online AccessGet full text

Cover

More Information
Summary:A third study used lofepramine as a comparitor, a more modern tricyclic with a much more benign anticholinergic side effect profile than its older cousins, which have an adverse event rate similar to the selective serotonin reuptake inhibitors. 2 Two of the three studies providing unambiguous data for the efficacy analysis were of paroxetine against amitriptyline.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ObjectType-Commentary-2
Competing interests: ASH is past investigator and speaker for companies producing all the drugs concerned.
ISSN:0959-8138
0959-8146
1468-5833
1756-1833
DOI:10.1136/bmj.327.7409.289-a